Mechanisms of neuromodulatory volume transmission
- PMID: 38789677
- PMCID: PMC11540752
- DOI: 10.1038/s41380-024-02608-3
Mechanisms of neuromodulatory volume transmission
Abstract
A wealth of neuromodulatory transmitters regulate synaptic circuits in the brain. Their mode of signaling, often called volume transmission, differs from classical synaptic transmission in important ways. In synaptic transmission, vesicles rapidly fuse in response to action potentials and release their transmitter content. The transmitters are then sensed by nearby receptors on select target cells with minimal delay. Signal transmission is restricted to synaptic contacts and typically occurs within ~1 ms. Volume transmission doesn't rely on synaptic contact sites and is the main mode of monoamines and neuropeptides, important neuromodulators in the brain. It is less precise than synaptic transmission, and the underlying molecular mechanisms and spatiotemporal scales are often not well understood. Here, we review literature on mechanisms of volume transmission and raise scientific questions that should be addressed in the years ahead. We define five domains by which volume transmission systems can differ from synaptic transmission and from one another. These domains are (1) innervation patterns and firing properties, (2) transmitter synthesis and loading into different types of vesicles, (3) architecture and distribution of release sites, (4) transmitter diffusion, degradation, and reuptake, and (5) receptor types and their positioning on target cells. We discuss these five domains for dopamine, a well-studied monoamine, and then compare the literature on dopamine with that on norepinephrine and serotonin. We include assessments of neuropeptide signaling and of central acetylcholine transmission. Through this review, we provide a molecular and cellular framework for volume transmission. This mechanistic knowledge is essential to define how neuromodulatory systems control behavior in health and disease and to understand how they are modulated by medical treatments and by drugs of abuse.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
- R01 DA056109/DA/NIDA NIH HHS/United States
- R01 NS083898/NS/NINDS NIH HHS/United States
- R01 MH113349/MH/NIMH NIH HHS/United States
- 31271/Brain and Behavior Research Foundation (Brain & Behavior Research Foundation)
- R01NS103484/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- R01DA056109/U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)
- LT0004/2022/Human Frontier Science Program (HFSP)
- R01NS083898/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- R01MH113349/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- R01 NS103484/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
